Intercept Pharmaceuticals Inc (NASDAQ:ICPT) major shareholder S.P.A. Genextra sold 750,000 shares of the business’s stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $105.07, for a total value of $78,802,500.00. Following the transaction, the insider now owns 6,095,578 shares in the company, valued at approximately $640,462,380.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Intercept Pharmaceuticals stock opened at $105.92 on Thursday. The company has a debt-to-equity ratio of 3.83, a current ratio of 5.98 and a quick ratio of 5.98. The stock has a market capitalization of $3.29 billion, a P/E ratio of -7.37 and a beta of -1.03. Intercept Pharmaceuticals Inc has a fifty-two week low of $51.05 and a fifty-two week high of $133.74.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.65) by $0.47. The firm had revenue of $47.00 million during the quarter, compared to analyst estimates of $48.24 million. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. Intercept Pharmaceuticals’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the company earned ($2.89) earnings per share. Equities research analysts anticipate that Intercept Pharmaceuticals Inc will post -10.35 earnings per share for the current fiscal year.
A number of analysts have recently issued reports on ICPT shares. BidaskClub raised Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. ValuEngine raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, September 13th. Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $113.00 target price on the stock in a research report on Tuesday, November 13th. Roth Capital started coverage on Intercept Pharmaceuticals in a research report on Wednesday, September 12th. They set a “buy” rating and a $192.00 target price on the stock. Finally, Raymond James lowered Intercept Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lifted their target price for the stock from $126.00 to $141.00 in a research report on Tuesday, October 2nd. They noted that the move was a valuation call. Seven research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $148.25.
Institutional investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board increased its holdings in Intercept Pharmaceuticals by 95.9% in the second quarter. State of Wisconsin Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock valued at $1,905,000 after buying an additional 11,111 shares during the last quarter. FMR LLC increased its holdings in Intercept Pharmaceuticals by 17.5% in the second quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock valued at $372,336,000 after buying an additional 661,542 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Intercept Pharmaceuticals by 104.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 110,805 shares of the biopharmaceutical company’s stock valued at $9,298,000 after buying an additional 56,556 shares during the last quarter. Asymmetry Capital Management L.P. bought a new stake in Intercept Pharmaceuticals in the second quarter valued at about $2,175,000. Finally, Rhumbline Advisers increased its holdings in Intercept Pharmaceuticals by 11.5% in the second quarter. Rhumbline Advisers now owns 21,153 shares of the biopharmaceutical company’s stock valued at $1,775,000 after buying an additional 2,181 shares during the last quarter. 63.62% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/12/06/intercept-pharmaceuticals-inc-icpt-major-shareholder-sells-78802500-00-in-stock.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Recommended Story: What are retained earnings?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.